Acute myeloid leukaemia+1
Not recruitingStudy of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation
Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation
- Disease:Acute myeloid leukaemiaMyelodysplastic syndrome
- Substances:Enasidenib MesilateIvosidenib
France- Participants:18–64 years · 65+ years
- Substances:Enasidenib Mesilate
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting









